Cargando…

Evaluation of the anti-RANKL monoclonal antibody in rheumatoid arthritis rats

OBJECTIVES: In this study, we aimed to investigate the therapeutic effect of anti-receptor activator of nuclear factor kappa-κB ligand (RANKL) monoclonal antibodies R748-1-1-1, R748-1-1-2 and R748-1-1-3 on rheumatoid arthritis (RA) in a rat model. MATERIALS AND METHODS: Gene cloning, hybridoma techn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Dawei, Zhao, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Turkish League Against Rheumatism 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208611/ https://www.ncbi.nlm.nih.gov/pubmed/37235123 http://dx.doi.org/10.46497/ArchRheumatol.2023.9240

Ejemplares similares

Individual and combining effects of anti-RANKL monoclonal antibody and teriparatide in ovariectomized mice
por: Tokuyama, Naoto, et al.
Publicado: (2015)

Is RANKL inhibition both anti-resorptive and anabolic in rheumatoid arthritis?
por: Sims, Natalie A., et al.
Publicado: (2015)

The importance of cell surface RANKL in rheumatoid arthritis
por: Krystufkova, O, et al.
Publicado: (2005)

Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis
por: Lim, Sung Ho, et al.
Publicado: (2022)

Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

15017 Monoclonal antibody use in rheumatoid arthritis: an evaluation of medical expenditure
por: Kelly, Robert A., et al.
Publicado: (2021)

Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate
por: Hensvold, Aase Haj, et al.
Publicado: (2015)

Majoon Chobchini attenuates arthritis disease severity and RANKL-mediated osteoclastogenesis in rheumatoid arthritis
por: Samarpita, Snigdha, et al.
Publicado: (2021)

Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies
por: Senolt, Ladislav
Publicado: (2019)

Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
por: Remuzgo-Martínez, Sara, et al.
Publicado: (2016)

RANKL is a therapeutic target of bone destruction in rheumatoid arthritis
por: Tanaka, Sakae
Publicado: (2019)

Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments
por: Chi, Xiao-Kai, et al.
Publicado: (2023)

Immunodiagnosis and therapeutic immunosuppression in rheumatoid arthritis with ior t1 (anti-CD6) monoclonal antibody
por: Montero, E, et al.
Publicado: (2002)

From discovery of RANKL to clinical application of anti-human RANKL antibody
por: Yasuda, Hisataka, et al.
Publicado: (2012)

Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
por: Hirabara, Shinya, et al.
Publicado: (2014)

Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis
por: Kim, Jeong Yeon, et al.
Publicado: (2012)

Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera
por: Matsuno, H, et al.
Publicado: (2003)

Pathogenic Role of Circulating Citrullinated Antigens and Anti-Cyclic Monoclonal Citrullinated Peptide Antibodies in Rheumatoid Arthritis
por: Won, Pureun, et al.
Publicado: (2021)

Rheumatoid Arthritis and Anti-Thyroid Antibodies
por: Yavasoglu, Irfan, et al.
Publicado: (2009)

Anti-BIP antibodies in rheumatoid arthritis
por: Panayi, GS, et al.
Publicado: (2003)

Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
por: Kay, Jonathan, et al.
Publicado: (2010)

Anti-carbamylated protein antibodies in rheumatoid arthritis patients and their association with rheumatoid factor
por: Othman, Maizatul A., et al.
Publicado: (2017)

OPG and RANKL in serum and synovial fluids of patients with rheumatoid arthritis, osteoarthritis and spondylarthropathy
por: Krystufkova, O, et al.
Publicado: (2003)

Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
por: Isaacs, JD, et al.
Publicado: (2005)

The association of anti-CCP antibodies with disease activity in rheumatoid arthritis
por: Serdaroğlu, Münevver, et al.
Publicado: (2008)

Generation mechanism of RANKL(+) effector memory B cells: relevance to the pathogenesis of rheumatoid arthritis
por: Ota, Yuri, et al.
Publicado: (2016)

High thioredoxin-1 levels in rheumatoid arthritis patients diminish binding and signalling of the monoclonal antibody Tregalizumab
por: Heim, Katharina, et al.
Publicado: (2016)

Effects of anti-mouse RANKL antibody on orthodontic tooth movement in mice
por: Yoshimatsu, Masako, et al.
Publicado: (2022)

Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis
por: Al-Shukaili, Ahmed, et al.
Publicado: (2012)

Propionibacterium freudenreichii Inhibits RANKL-Induced Osteoclast Differentiation and Ameliorates Rheumatoid Arthritis in Collagen-Induced Arthritis Mice
por: Yeom, Jiah, et al.
Publicado: (2021)

Anti-cyclic citrullinated peptide antibody predicts the development of rheumatoid arthritis in patients with undifferentiated arthritis
por: Li, Chun, et al.
Publicado: (2019)

Specificity of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis
por: Trier, Nicole H., et al.
Publicado: (2019)

A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell–activating factor monoclonal antibody, for rheumatoid arthritis
por: Greenwald, Maria, et al.
Publicado: (2014)

Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors
por: Tanaka, Toshio, et al.
Publicado: (2014)

N-acetyl-l-cysteine controls osteoclastogenesis through regulating Th17 differentiation and RANKL in rheumatoid arthritis
por: Kim, Hae-Rim, et al.
Publicado: (2019)

Bone Metabolism and RANKL/OPG Ratio in Rheumatoid Arthritis Women Treated with TNF-α Inhibitors
por: Jura-Półtorak, Agnieszka, et al.
Publicado: (2021)

Distinct patterns of RANKL/osteoprotegerin system modulation through anti-tumour necrosis factor and corticosteroid therapy in rheumatoid arthritis synovium
por: Catrina, AI, et al.
Publicado: (2005)

Anti-Ro/SSA antibodies in rheumatoid arthritis (RA)
por: Franceschini, F, et al.
Publicado: (2003)

The association of serum RANKL levels with disease activity and hematological parameters in Syrian patients with rheumatoid arthritis
por: Hussein, Rama, et al.
Publicado: (2022)

Hyaluronan Inhibits Tlr-4-Dependent RANKL Expression in Human Rheumatoid Arthritis Synovial Fibroblasts
por: Watanabe, Tatsuo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6n1hq70sted7pkk605irt6krnt